Introduction
Camptothecin is known as an alkaloid isolated from Chinese tree Camptotheca acuminata1). 7-Ethyl-10-hydroxycamptothecin (SN-38) is a semi-synthetic derivative of camptothecin, and irinotecan hydrochloride (CPT-11) is a prodrug of SN-382,3). CPT-11 is known to be very effective against various tumors in vivo4-6). Although SN-38 is much higher potent in vitro than CPT-11, CPT-11 exhibits better efficacy in vivo , which is considered due to the difference of their pharmacokinetic characteristics2). Since camptothecin works time-dependently7, 8) , it is suggested that raising the drug retention in the body might cause higher efficacy. CPT-11 is considered to be high potent in vivo due to much longer retention of SN-30 in the body fluid2). Therefore, in the previous studies, the dosage forms, implant tablet and microspheres, showing prolonged release of irinotecan were developed using poly (DL-lactic acid) (PLA) or poly (DL-lactic acid-co-glycolic acid) (PLGA)9-11). As a result of their in vivo antitumor tests, these dosage forms exhibited equivalent or higher effect against P388 leukemia in peritoneal fluid by intraperitoneal administration10). On the other hand, these prolonged release systems were less effective against subcutaneously inoculated sarcoma 180 solid tumor by intraperitoneal administration10). Therefore, simple prolonged release of irinotecan is considered to bring about better effect only when the drug is released directly and closely to the tumor cells, but it is less effective to the tumor distant from the in- (Fig. 4) . When NP-S (3 mg irinotecan eq./kg) was admin- The horizontal axis represents the particle di- containing nanoparticles were newly developed using PLA and PEG-M. The mean particle diameter of the obtained nanoparticles was small (150nm), which was adequate for avoidance of the trap by reticuloendothelium (Fig. 1 ). Such reticuloendothelial entrapment should also be suppressed more by hydrophilic coating of particle surface by the surfactant, PEG-M ; the improvement of plasma retention by hydrophylic coating has been reported for PLGA nanospheres14-16). The nanoparticles with such particle properties, included in the present nanoparticle-containing suspension (NP-S), were considered to have a potency to accumulate into diseased parts such as tumor tissues where the permeability of the blood vessel was enhanced ; such a property is known as enhanced permeability and retention (EPR) effect17). The NP-S containing such nanoparticles was characterized in vitro and in vivo.
The in vitro features of NP-S was found as follows : The nanoparticles were formed by coprecipitation of waterinsoluble PLA and low water-soluble irinotecan, and subsequent coating by PEG-M ; the solubility of the used drug powder was less than 0.5mg/mL at room temperature. When the nanoparticles were separated by ultra-centrifugation or gel-filtration, the collected amount was greater in gel-filtration than in ultra-centrifugation. All of PEG-M was not supposed to contribute to coating of particle surface, and the particles with a diameter much smaller than the mean diameter were considered not to be recovered by ultracentrifugation because of much slow sedimentation ; actually, smaller particles with a diameter of 20-30nm were observed in Fig. 1 . On the contrary, such smaller particles could be gathered in gel-filtration, resulting in the higher collected amount in this separation method. Irrespective of the difference of the collected amounts, the drug recoveries were similar in ultra-centrifugation and gel-filtration. Smaller particles should be lost in ultra-centrifugation, while drugloaded particles might be lost to some extent in gel-filtration due to trap by the column. As a result, at least 20% of the drug was found recovered in the nanoparticles.
The nanoparticles separated by ultra-centrifugation was difficult to re-suspend in water, and their particle characteristics were changed when suspended by sonication. The nanoparticle-containing fractions separated by gel-filtration had to be condensed by evaporation of water in order to use further in the in vivo experiments. However, by this condensation, particle characteristics such as drug content were changed to some extent. Therefore, the nanoparticles separated by these methods were not used for the in vivo experiments. On the other hand, NP-S reproducibly showed similar values of yield, particle diameter and drug recovery for the nanoparticles at every time. Thus, in the present study, NP-S, obtained initially, was used for in vivo experiments without separation of nanoparticles. When NP-S was diluted by addition of water, some drug release was found, but the drug release from the nanoparticles was not tested in detail in this study. The drug release might not be estimated correctly by ultra-centrifugation or gel-filtration because such operations might affect the particle characteristics. It appears to be adequate for the drug release test to measure by another method such as membrane transport18). The release property remained to be a future subject.
Antitumor effect against sarcoma 180 solid tumor tended to be higher in NP-S than in CPT-11 solution (Fig. 2) . This suggested NP-S should be highly potent against sarcoma 180 solid tumor. The toxic side effects of NP-S were considered to be low due to slight body weight change (Fig. 3) and no diarrhea. The plasma concentration-time profiles showed the level of total irinotecan (incorporated plus free) for NP-S (Fig. 4) . NP-S tended to retain irinotecan longer in the plasma than CPT-11 solution. Further, the AUG , MRT and VRT values were larger in NP-S than CPT-11 aqueous solution, suggesting that the NP-S might give better and longer retention of irinotecan in the plasma ( Table 1) . The nanoparticles circulating in the plasma might be accumulated into the tumor tissue based on EPR effect, which might be related to the result of antitumor effect. Although SN-38 was not analyzed in detail, it could be detected fairly long in a similar HPLC method ; SN-38 was detected at more than 3 and 2 ng/mL at 8 and 24h post-injection of NP-S, respectively (data not shown). These plasma concentration data supported the potency of NP-S to raise the therapeutic efficacy. Recently, nanoparticles were prepared using PLA, irinotecan and poly (ethylene glycol)-block-poly (propylene glycol)-block-poly (ethylene glycol) (PEG-PPG-PEG) in the similar manner, that is, by the coprecipitation method, separated by gel-filtration and examined in vitro and in vivo 19) , and they were named PEG-PPG-PEG-NP in the present paper. PEG-PPG-PEG-NP showed the particle diameters of 80-210 nm and drug content of 4.5% (w / w), which were considered fairly similar to those of the present NP-Scontained nanoparticles. PEG-PPG-PEG-NP showed longer plasma retention than CPT-11 solution ; the plasma concentration in PEG-PPG-PEG-NP was lower at initial periods but retained longer at the latter phase as compared with CPT-11 solution. NP-S showed the similar plasma pharmacokinetic profile to PEG-PPG-PEG-NP, which would be based on NP-S-contained nanoparticles. However, the difference in the plasma concentration-time curve from CPT-11 solution appeared to be marked in PEG-PPG-PEG-NP than in NP-S, which was considered because NP-S contained the free form of irinotecan to a fair extent. The SN-38 plasma level seemed to be better maintained in the order of PEG-PPG-PEG-NP >NP-S >CPT-11 solution. This also indicated that SN-38 might appear in parallel with CPT-11. This result would be caused by nanoparticles, and PEG-PPG-PEG-NP prepared by full separation might influence the SN-38 level more than NP-S obtained without separation.
The plasma pharmacokinetics of NS-P were considered to support the advantageous properties of NP-S against sarcoma 180 solid tumor. Simple prolonged release systems having been reported previously were much less effective against sarcoma 180 solid tumor than CPT-11 solution, resulting in difficulty in enhancement of efficay by those simple prolonged release dosage systems9-11). On the other hand, the present NP-S tended to show higher efficacies than CPT-11 solution even at a fairly low dose. Therefore, the efficay of NP-S were supposed not only based on modification of plasma pharmacokinetics of irinotecan but also due to their biodisposition properties probably leading to EPR effect by the NP-S-contained nanoparticles ; the biodisposition of the nanoparticles into tissues including tumor will have to be examined to elucidate mechanism of their drug action more clearly. In the antitumor studies, the drug was intravenously injected at 20mg irinotecan eq./kg/day at 7, 8 and 9 d post-inoculation. Therefore, pharmacokinetics and appearane of SN-38 might have to be examined at this high dose for exact evaluation of NP-S efficacy. However, the present pharmacokinetic results are considered to reveal the biological properties of NP-S fundamentally and will be available to a fair extent for discussion of the results of antitumor studies. The toxic side effects such as body weight decrease and diarrhea were not observed in antitumor studies. This was consistent with the reported results that repeated and high doses, for example daily injections of 50 (i.p.) and 60 (i.v.) mg CPT-11/kg for several days, were required to produce the diarrhea in mice and rats, respectively 20,21) ; reportedly in human , severe diarrhea was caused even in the i.v. infusion over 90 min at 120 mg CPT-11/m2 near clinical use22). Namely, in this animal experiment, the present dose were considered not to be high enough to cause actute toxicities such as diarrhea. Although the body weight increase tended to be better in CPT-11 solution than in NP-S at the latter periods, it could not be simply judged that CPT-11 was less toxic than NP-S, because tumor weight influenced the body weight. Examination at higher doses will be needed for comparison of toxic side effects of NP-S with those of CPT-11 solution.
In conclusion, the present suspension included the irinotecan-containing nanoparticles with the particle diameter enough to allow escape from the trap by reticuloendothelium. The nanoparticle-containing suspension significantly suppressed the growth of sarcoma 180 solid tumor, when the EPR effect might contribute to the efficacy. Thus, the nanoparticle-containing suspension was possibly useful as a new therapeutic formation of irinotecan. Since the biodistribution of the drug in the tumor has not been investigated, the biodisposition features of the nanoparticle-containing suspension will have to be investigated in more detail to elucidate the mechanism of their drug action more clearly. Further, in order to more exactly evaluate the efficacy of the nanoparticles themselves, their physical stability and separation manner will have to be pursued further.
